CapsoVision Inc (CV) FinancialsCVCapsoVision Inc

CapsoVision Inc (CV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Products (capsules and capsule reading devices), accounting for 90.5% of total sales, equivalent to $2.53M. Another important revenue stream is Services (cloud-based video delivery and reading services). Understanding this composition is critical for investors evaluating how CV navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, CapsoVision Inc maintains a gross margin of 51.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -208.07%, while the net margin is -205.35%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CV converts its operational activities into shareholder value.

In the context of the broader market, CV competes directly with industry leaders such as TLSI and MYGN. With a market capitalization of $303.28M, it holds a significant position in the sector. When comparing efficiency, CV's gross margin of 51.36% stands against TLSI's 86.78% and MYGN's 66.60%. Such benchmarking helps identify whether CapsoVision Inc is trading at a premium or discount relative to its financial performance.

CapsoVision reported a 10% year-over-year revenue growth in Q2 2026, driven by a 13% increase in capsule shipments, indicating sustained market demand. Despite this, the company has been facing significant net income losses, with a reported loss of $7.48 million in Q2 2026.